NASDAQ:ABUS
Arbutus Biopharma Corp
Arbutus Biopharma Corp's revenue grew 128.2% in fiscal 2025 to $14.1M while operating margin rose to −271.0%. Free cash flow was −$39.6M, −281.5% of revenue, and the diluted share count rose 3.2%.Summary generated from Arbutus Biopharma Corp's SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$14.1M
Revenue growth+128.2%
Revenue, 5-yr CAGR+15.3%
Gross marginn/a
Operating margin−271.0%
Net margin−237.9%
ROIC−50.4%
Return on equity−38.5%
Debt / equity0.00
Free cash flow−$39.6M
FCF margin−281.5%
Share count change+3.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 | 39 | 18 | 6 | 14 |
| Operating income | −74 | −65 | −78 | −76 | −38 |
| Net income | −76 | −69 | −73 | −70 | −34 |
| Free cash flow | −68 | −36 | −87 | −65 | −40 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 7, 2026 - 8-KOther events
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KTermination of a material agreement
Jul 16, 2026 - 8-KDirector or officer change
May 27, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026